Intelligent controllable conjunctival sac continuous administration device

Abstract

The invention discloses an intelligent controllable conjunctival sac continuous drug delivery device which comprises a drug storage tank, a micro pump, a conjunctival sac adapter, a head band structure and an intelligent control system. The medicine storage tank is used for storing medicine, and the initial volume of the medicine storage tank is set as V0; the micro pump conveys the medicine to the conjunctival sac adapter at the rate of flow Q according to a control signal S generated by the intelligent control system, and the conjunctival sac adapter accurately releases the medicine into the conjunctival sac of a patient through the medicine outlet hole; the intelligent control system comprises a central processing unit, a humidity sensor, a timing module, a medicine action time module, a data storage module and a user setting interface, the multi-mode medicine conveying function is achieved through timing control, humidity response control and medicine action time control, and the conveying flow is dynamically adjusted through multi-signal fusion and a humidity feedback mechanism. The device overcomes the defects that traditional eye drops are low in absorption efficiency, an implantable device is high in risk and an existing micro pump system is insufficient in intelligence, and automatic medicine conveying is achieved.

Description

Technical Field

[0001] The present invention relates to the technical field of conjunctival sac drug delivery, and in particular to an intelligent controllable conjunctival sac continuous drug delivery device. Background Art

[0002] Eye diseases are common health problems worldwide, including dry eyes, conjunctivitis, glaucoma, and postoperative care, which require continuous drug delivery treatment. Traditional ocular drug delivery methods are mainly based on eye drops, which are simple to operate, but the drug has a short residence time on the ocular surface, low absorption rate, and frequent use may lead to poor patient compliance. In addition, precise control of ocular drug delivery is difficult to achieve in complex environments (such as dry climates or nighttime sleep), which seriously affects the treatment effect. In order to improve these problems, in recent years, researchers have tried to design a variety of continuous drug delivery systems and devices, such as contact lens-type drug delivery systems, implantable devices, and micro-pump control systems to improve drug utilization and therapeutic effects.

[0003] Disadvantages of eye drops: Eye drops are the most commonly used method of ocular drug delivery, but their shortcomings are obvious:

[0004] Low drug absorption efficiency: Most of the drugs dropped into the ocular surface will be lost with tears, and only 5%-10% of the drugs will be absorbed by the cornea, resulting in low actual efficacy.

[0005] Short residence time: The drug usually stays on the ocular surface for only a few minutes, which cannot meet the needs of continuous treatment.

[0006] Poor compliance: Patients need to take drops of medicine frequently. Especially for the elderly or patients with limited mobility, it is difficult to accurately control the time and dosage of medication, resulting in unstable treatment effects.

[0007] Contact lens drug delivery device: Contact lens drug delivery device achieves slow release by loading the drug into the contact lens material. This method prolongs the retention time of the drug to a certain extent, but there are also the following problems:

[0008] Poor comfort: Long-term wearing may cause eye discomfort to patients, especially those with dry eyes, and may aggravate eye dryness and inflammation.

[0009] Uneven drug release: The drug release rate from contact lenses is difficult to precisely control, and the amount of drug released may not be sufficient to achieve therapeutic concentrations.

[0010] Limited scope of application: Contact lens-type devices are mainly suitable for short-term treatment, and patients who take long-term medications still need to replace contact lenses frequently.

[0011] Implantable drug delivery devices: Implantable devices (such as subconjunctival drug microdevices) are implanted into ocular tissues through surgery and use a sustained-release mechanism to achieve long-term drug delivery. This type of technology performs well in precision drug delivery, but it also has shortcomings:

[0012] High surgical risk: The implant surgery itself may cause risks such as infection and inflammation and is not suitable for all patients.

[0013] The device is not adjustable: the drug release rate is fixed and cannot dynamically respond to individual patient needs or environmental changes.

[0014] Micro pump control device: Micro pump control device uses mechanical drive or electrochemical control of the pump to deliver drugs to the target site, with good accuracy and controllability. However, the existing micro pump control device also has the following shortcomings:

[0015] Low level of intelligence: Most micropump systems cannot automatically adjust the drug delivery volume according to the external environment (such as humidity changes) and lack real-time response capabilities.

[0016] Complex operation: Some devices require external equipment assistance, which increases the patient's operating burden.

[0017] Poor portability: Many existing devices are large in size and cannot meet the requirements of portability and daily use.

[0018] In summary, current ocular drug delivery technologies have significant deficiencies in the following aspects:

[0019] Lack of dynamic response capability: Most existing devices use a fixed delivery mode and cannot be dynamically adjusted according to the actual needs of patients (such as humidity, drug action time, etc.), resulting in insufficient drug delivery accuracy.

[0020] Poor patient compliance: The use of eye drops and other external devices requires frequent operation by patients, which can easily lead to inconvenience in use, especially for patients with limited mobility or long-term treatment.

[0021] Insufficient device comfort: Implantable devices have surgical risks, and contact lens-type devices are uncomfortable to wear, and neither can meet the comfort needs of long-term treatment.

[0022] Difficulty in achieving portability: Some devices are large or rely on external power sources, which affects patients’ mobility and convenience of daily use.

[0023] To this end, we designed an intelligent and controllable conjunctival sac continuous drug delivery device to solve the above problems. Summary of the invention

[0024] The purpose of the present invention is to solve the technical problems raised in the above-mentioned background technology and to provide an intelligent controllable conjunctival sac continuous drug delivery device.

[0025] The above-mentioned object of the present invention is achieved by the following technical solutions:

[0026] The solution of the present invention provides an intelligent controllable conjunctival sac continuous drug delivery device, comprising:

[0027] Medicine storage tank 1: used to store medicine, with an initial volume of V0 in mL;

[0028] Micro pump 2: used for delivering the drug from the drug storage tank to the conjunctival sac adapter at a flow rate Q according to the total control signal S;

[0029] Conjunctival sac adapter 3: a hemispherical body with a drug-conducting channel inside, which releases the drug into the patient's conjunctival sac through the drug outlet holes at the bottom and top, and is made of hydrogel material or silicone hydrogel material;

[0030] Headband structure 4: used to fix the medicine storage tank 1 and the micro pump 2;

[0031] Intelligent control system: including central processing unit, humidity sensor, timing module, drug action time module, user setting interface, data storage module and signal processing module, used to realize the following functions:

[0032] Time-based timing drug administration control: by setting the time interval Δt, a timing signal S1 is generated;

[0033] Dynamic control based on ambient humidity: The real-time humidity H is detected by the humidity sensor and compared with the humidity threshold H th Comparison to generate humidity signal S2;

[0034] Efficacy control based on drug action time: according to the system cumulative time t and the drug action time setting value t e , generating a therapeutic effect signal S3;

[0035] Multi-signal fusion control: According to the logical fusion of S1, S2, and S3, a total control signal S is generated to control the start of the micro pump;

[0036] Feedback mechanism optimizes drug delivery: The drug delivery flow rate Q is adjusted through the humidity feedback mechanism to ensure the accuracy of drug delivery.

[0037] As a preferred technical solution of the present invention, the generation formula of the timing control signal S1 is:

[0038]

[0039] Wherein: S1: timing control signal; t: system cumulative running time; Δt: timing interval set by the user. When S1=1, the micro pump is triggered to work.

[0040] As a preferred technical solution of the present invention, the formula for generating the humidity control signal S2 is:

[0041]

[0042] Where: S2: humidity control signal; H: real-time humidity value, detected by humidity sensor; H th : Humidity threshold, which can be set by the user through the intelligent control system. When S2=1, the micro pump is started to deliver the drug.

[0043] As a preferred technical solution of the present invention, the generation formula of the drug action time control signal S3 is:

[0044]

[0045] Where: S3: drug action time control signal; t: system cumulative running time; t e : Drug action time setting value. When S3=1, the micro pump is triggered to deliver drugs to maintain the therapeutic effect.

[0046] As a preferred technical solution of the present invention, the total control signal S is integrated with multiple control signals through the following formula:

[0047] S = S1 ∨ S2 ∨ S3;

[0048] Wherein: S: total control signal; ∨: logical "OR" operator, when S=1, the micro pump starts drug delivery.

[0049] As a preferred technical solution of the present invention, the drug delivery flow rate Q is calculated by the following formula:

[0050] Q=k·t p ;

[0051] Where: Q: drug delivery flow rate, in mL; k: micro pump delivery volume per unit time, in mL / s; t p : Working time of micro pump, in seconds.

[0052] The intelligent controllable conjunctival sac continuous drug delivery device according to any one of claims 1 to 6, characterized in that the humidity threshold H th It can be adjusted dynamically according to the following formula:

[0053] H th =H avg +ΔH;

[0054] Where: H avg : The average value of historical humidity data; ΔH: Humidity deviation adjustment.

[0055] As a preferred technical solution of the present invention, the current remaining volume V of the drug is calculated by the following formula:

[0056]

[0057] Where: V: the current remaining volume of the drug; V0: the initial volume of the drug storage tank; Q i : the drug flow rate of the ith delivery; n: the number of drug deliveries currently completed.

[0058] As a preferred technical solution of the present invention, the humidity feedback mechanism adjusts the drug delivery flow rate Q, and the adjustment formula is:

[0059] Q=Q0+α(H th -H);

[0060] Where: Q0: basic transport capacity; α: humidity feedback adjustment coefficient; H th : Humidity threshold; H: Real-time humidity value.

[0061] As a preferred technical solution of the present invention, the intelligent control system integrates multiple control strategies through the following formula to generate an optimized control signal:

[0062] S=sigmoid(w1S1+w2S2+w3S3);

[0063] Among them: The activation function is defined as:

[0064]

[0065] w1, w2, w3: are the weights of the timing control, humidity control and drug action time control signals respectively; S1, S2, S3: are the timing control signal, humidity control signal and drug action time control signal respectively.

[0066] Compared with the prior art, the present invention has the following beneficial effects:

[0067] 1. The present invention is composed of a medicine storage tank, a micro pump, a conjunctival membrane adapter and other structures. It has a simple structure and can be carried by patients. The structure of the device is similar to that of contact lenses, which is comfortable to wear and will not cause any discomfort to patients.

[0068] 2. The solution of the present invention realizes dynamic regulation and precise management of drug delivery through an intelligent control system, overcoming the shortcomings of the prior art that the drug release rate is fixed and does not respond to individual needs. By combining timing control, humidity response control and drug action time control, the device can flexibly adjust the drug administration mode according to the actual needs of the patient (such as treatment stage, environmental humidity, drug metabolism rules, etc.), ensuring that the patient can obtain accurate drug dosage and efficacy under different environmental and disease conditions. In addition, the introduction of multi-signal fusion strategy and activation function makes the drug delivery process more intelligent and smooth, significantly improving the accuracy and personalized effect of treatment.

[0069] 3. The technical solution of the present invention reduces the frequency of manual operation of patients through an automated drug delivery mode, which significantly improves the use compliance, especially for the elderly or patients with limited mobility. Compared with the traditional eye drops that require frequent manual operation, this device can deliver drugs regularly and automatically, and users can set key parameters (such as time intervals, humidity thresholds, etc.) through a simple interface. At the same time, the device is designed to be wearable, small in size, light in weight, and highly comfortable. It will not interfere with the patient's daily activities and is especially suitable for patients who need stable treatment for a long time. In addition, the remaining drug monitoring function can also promptly remind patients to replace the drug storage tank, further improving the user experience of the device.

[0070] 4. The present invention overcomes the shortcomings of eye drops, contact lens-type devices, and implantable devices in terms of low drug absorption efficiency, poor comfort, and high surgical risks. By combining an intelligent micropump and a conjunctival sac adapter, the drug can act directly on the target area of ​​the eye, greatly improving the drug absorption efficiency and therapeutic effect. The humidity response mode is particularly suitable for patients with dry eyes or in scenarios where the ambient humidity fluctuates greatly, while the timing mode and drug action time mode can meet the needs of postoperative care and chronic disease treatment. In addition, the device has good adaptability in a variety of scenarios such as medical institutions, home care, and outdoor use, showing broad application prospects and market value. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0072] Figure 1 It is a system block diagram of an intelligent control system for an intelligent controllable conjunctival sac continuous drug delivery device;

[0073] Figure 2It is a schematic diagram of the structure of an intelligent controllable conjunctival sac continuous drug delivery device;

[0074] Figure 3 A schematic diagram of the structure of a headband structure of an intelligent controllable conjunctival sac continuous drug delivery device;

[0075] Figure 4 A schematic diagram of the internal structure of a box body of an intelligent controllable conjunctival sac continuous drug delivery device;

[0076] Figure 5 It is a structural schematic diagram of a conjunctival sac adapter of an intelligent controllable conjunctival sac continuous drug delivery device;

[0077] Figure 6 The present invention is a cross-sectional view of a conjunctival sac adapter of an intelligent controllable conjunctival sac continuous drug delivery device.

[0078] In the figure: 1 medicine storage tank; 2 micro pump; 3 conjunctival sac adapter; 4 headband structure; 5 box body; 6 battery; 7 circuit board; 8 humidity sensor; 9 circuit board; 10 touch display screen. DETAILED DESCRIPTION

[0079] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0080] The following is combined with Figure 1-Figure 6 , the specific implementation methods of the present invention are described in detail.

[0081] Example 1: Hardware structure of the intelligent controllable conjunctival sac continuous drug delivery device:

[0082] Medicine storage tank 1: used to store medicine, with an initial volume of V0 in mL;

[0083] Micro pump 2: used for delivering the drug from the drug storage tank to the conjunctival sac adapter at a flow rate Q according to a control signal S;

[0084] The conjunctival sac adapter 3 is a hemispherical body with a drug-conducting channel inside, which releases the drug into the patient's conjunctival sac through the drug outlet holes at the bottom and the top; the conjunctival sac adapter 3 is a hollow structure, and its cavity is connected to the drug-conducting tube connected to the micro pump 2; the shape of the conjunctival sac adapter 3 is the same as that of a contact lens, and it is made of a hydrogel material or a silicone hydrogel material;

[0085] Headband structure 4: used to fix the medicine storage tank 1 and the micro pump 2;

[0086] The medicine storage tank 1 and the micro pump 2 are both arranged in the box body 5. The box body 5 is also provided with a battery 6 and a circuit board 7. The outer wall of the box body 5 is also provided with a humidity sensor 8 and a touch display screen 10. The box body 5 is arranged on the outer wall of the headband structure 4.

[0087] When in use, the headband structure 4 is put on the head, and then the conjunctival sac adapter 3 is brought to the patient's eyes.

[0088] Embodiment 2: Hardware and software implementation of intelligent control system:

[0089] The intelligent control system is the core module of the device, namely the circuit board 9 in the figure, which includes both hardware and software.

[0090] Hardware structure: Central processing unit (CPU): An embedded processor (such as STM32 series microcontroller) is used as the main controller to run the drug delivery algorithm and coordinate hardware execution.

[0091] Humidity sensor 8: A high-precision digital humidity sensor (such as DHT22) is selected to detect the ambient humidity H in real time. The detection accuracy is ±1%, and the H response time is less than 5 seconds.

[0092] Timing module: The RTC (real-time clock) module integrated in the processor is used to record the system running time t and supports user-defined timing control intervals.

[0093] Data storage module: EEPROM storage chip with I2C interface is used to record the drug delivery history, including the amount of drug delivered each time. i , remaining volume V, humidity change trend H(t), etc.

[0094] User setting interface: including a touch screen (10), the user sets parameters (such as Δt, H th ,t e The display screen will provide real-time feedback on the setting results and operating status.

[0095] Software functions: The system embedded software adopts modular design, including data acquisition module, control signal generation module, flow calculation module and historical data management module.

[0096] The software has built-in control strategy logic to achieve multi-signal fusion control (S=S1∨S2∨S3) and activation function smoothing:

[0097] S=sigmoid(w1S1+w2S2+w3S3)).

[0098] Through the collaborative work of hardware and software, the system achieves dynamic optimization control of drug delivery.

[0099] Example 3: Application of timing controlled drug administration mode:

[0100] In the timing control mode, the user sets the time interval Δt by pressing a button, for example, setting it to deliver medicine every 4 hours. The system accumulates time through the timing module, and when tmodΔt=0 is met, the system generates a timing signal S1=1, triggering the micro pump to operate.

[0101] Drug delivery example: User sets micropump run time t p =15s, unit flow coefficient k = 0.25mL / s; the delivery volume each time is calculated as:

[0102] Q dose = k·t p =0.25mL / s×15s=3.75mL;

[0103] The system records the remaining volume V of the drug, with an initial value of V0 = 50 mL, and is updated after each delivery:

[0104] V=VQ dose ;

[0105] For example, after 3 deliveries, the remaining drug volume is:

[0106] V = 50-3 × 3.75 = 38.75 mL;

[0107] This mode is suitable for patients who need to refill medications at fixed intervals, such as patients with chronic eye diseases who need to maintain drug levels over the long term.

[0108] Example 4: Application of humidity response control:

[0109] The humidity response mode can dynamically adjust the drug delivery amount according to changes in ambient humidity. It is suitable for patients whose dry eyes are greatly affected by environmental changes (such as people who stay in air-conditioned rooms or high-temperature and dry areas for a long time).

[0110] Humidity feedback mechanism to optimize delivery example: User sets humidity threshold H th =50%, basic flow Q0 = 0.15mL / s, adjustment coefficient α = 0.01mL / s. The current detected ambient humidity H = 35%, the drug flow calculation formula is:

[0111] Q=Q0+α·(H th -H),

[0112] Q=0.15+0.01·(50-35)=0.3mL / s,

[0113] The micro pump runs at the calculated flow rate Qt p=10s, the amount of drug delivered each time is:

[0114] Q dose =Q·t p =0.3mL / s×10s=3.0mL;

[0115] The humidity response mode enables dynamic adjustment of the delivery volume, which can accurately compensate for the degree of eye dryness caused by decreased humidity.

[0116] Example 5: Sustained delivery of drug action time control:

[0117] The drug action time control mode is based on the drug action time t set by the user. e To maintain the efficacy of the drug. For example, the user sets t e = 6 hours. When the system cumulative time t satisfies tt e ≥0, trigger signal S3=1.

[0118] Drug delivery example: Micro pump operating parameters: Q = 0.2mL / s, t p =12s;

[0119] Calculation of delivery volume:

[0120] Q dose =Q·t p =0.2mL / s×12s=2.4mL;

[0121] This mode is suitable for scenarios where drugs need to be replenished according to the half-life of the drugs, such as long-term use of anti-inflammatory or anti-allergic drugs.

[0122] Example 6: Comprehensive application of multi-signal fusion:

[0123] In the multi-signal fusion mode, the system integrates timing control S1, humidity control S2, and drug action time control S3, and optimizes the control signal through the following formula:

[0124] S=sigmoid(w1S1+w2S2+w3S3);

[0125] Among them: w1=0.5, w2=0.3, w3=0.2 are weights;

[0126] The activation function sigmoid(x) is defined as:

[0127]

[0128] For example, when S1=1, S2=1, S3=0:

[0129] x=0.5·1+0.3·1+0.2·0=0.8;

[0130]

[0131] This signal serves as the starting strength of the micro pump, flexibly controlling the delivery frequency and flow rate to adapt to complex environmental requirements.

[0132] Example 7: Monitoring and reminding of remaining amount of medicine:

[0133] The system monitors the remaining drug amount V in real time and updates it through the following formula:

[0134]

[0135] For example, the user's initial drug volume V0 = 100 mL, and the delivery volume Q i =3mL, after 20 transfers:

[0136] V = 100-20 × 3 = 40 mL;

[0137] When V <V min When the liquid level reaches 10mL, the system will remind the user to replace the medicine storage tank through a buzzer.

[0138] Example 8: Combined application in specific scenarios:

[0139] The device of the present invention can be widely used in the following different scenarios:

[0140] Medical institution scenario: Used for continuous delivery of eye drugs to patients after surgery to ensure postoperative recovery.

[0141] Home use scenario: Chronic dry eye patients can dynamically replenish eye moisture through humidity response mode.

[0142] Travel scenario: Users can set the timing mode during long journeys to replenish medications on time and reduce manual operations.

[0143] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. An intelligent controllable conjunctival sac continuous drug delivery device, characterized in that: include: Medicine storage tank (1): used to store medicine, with an initial volume of V0 in mL; A micro pump (2) is used to deliver the drug from the drug storage tank to the conjunctival sac adapter at a flow rate Q according to a total control signal S; Conjunctival sac adapter (3): a hemispherical body with a drug-conducting channel inside, which releases the drug into the patient's conjunctival sac through drug outlet holes at the bottom and top, and is made of a hydrogel material or a silicone hydrogel material; Headband structure (4): used to fix the medicine storage tank (1) and the micro pump (2); Intelligent control system: including central processing unit, humidity sensor, timing module, drug action time module, user setting interface, data storage module and signal processing module, used to realize the following functions: Time-based timing drug administration control: by setting the time interval Δt, a timing signal S1 is generated; Dynamic control based on ambient humidity: The real-time humidity H is detected by the humidity sensor and compared with the humidity threshold H th Comparison to generate humidity signal S2; Efficacy control based on drug action time: according to the system cumulative time t and the drug action time setting value t e , generating a therapeutic effect signal S3; Multi-signal fusion control: According to the logical fusion of S1, S2, and S3, a total control signal S is generated to control the start of the micro pump; Feedback mechanism optimizes drug delivery: The drug delivery flow rate Q is adjusted through the humidity feedback mechanism to ensure the accuracy of drug delivery.

2. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The generation formula of the timing control signal S1 is: Wherein: S1: timing control signal; t: system cumulative running time; Δt: timing interval set by the user. When S1=1, the micro pump is triggered to work.

3. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The generation formula of the humidity control signal S2 is: Where: S2: humidity control signal; H: real-time humidity value, detected by humidity sensor; H th : Humidity threshold, which can be set by the user through the intelligent control system. When S2=1, the micro pump is started to deliver the drug.

4. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The generation formula of the drug action time control signal S3 is: Where: S3: drug action time control signal; t: system cumulative running time; t e : Drug action time setting value, when S3=1, the micro pump is triggered to deliver drugs to maintain the therapeutic effect.

5. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The total control signal S is integrated with multiple control signals by the following formula: S = S1 ∨ S2 ∨ S3; Wherein: S: total control signal; ∨: logical "OR" operator, when S=1, the micro pump starts drug delivery.

6. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The drug delivery flow rate Q is calculated by the following formula: Q=k·t p ; Where: Q: drug delivery flow rate, in mL; k: micro pump delivery volume per unit time, in mL / s; t p : Working time of micro pump, in seconds.

7. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 3, characterized in that: The humidity threshold H th It can be adjusted dynamically according to the following formula: H th =H avg +ΔH; Where: H avg : The average value of historical humidity data; ΔH: Humidity deviation adjustment.

8. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The current remaining volume V of the drug is calculated by the following formula: Where: V: the current remaining volume of the drug; V0: the initial volume of the drug storage tank; Q i : the drug flow rate of the ith delivery; n: the number of drug deliveries currently completed.

9. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The humidity feedback mechanism adjusts the drug delivery flow rate Q, and the adjustment formula is: Q=Q0+α(H th -H); Where: Q0: basic delivery; α: humidity feedback adjustment coefficient; H th : Humidity threshold; H: Real-time humidity value.

10. The intelligent controllable conjunctival sac continuous drug delivery device according to claim 1, characterized in that: The intelligent control system integrates multiple control strategies to generate optimized control signals through the following formula: S=sigmoid(w1S1+w2S2+w3S3); Among them: The activation function is defined as: w1, w2, w3 are the weights of the timing control, humidity control and drug action time control signals respectively; S1, S2, S3 are the timing control signal, humidity control signal and drug action time control signal respectively.

Images